India tests Agni-5 missile; Merck's Covid-19 pill; Snap hits 100 million users mark in India; and a chat with Mohit Yadav on REVOS's P2P charging network

India successfully tested its surface-to-surface ballistic missile Agni-5 on Thursday. According to a statement by the Ministry of Defence, it can strike targets at ranges up to 5,000km with a very high degree of accuracy. Merck, the US-based pharma company, has signed a licensing agreement with Medicines Patent Pool (MPP) to allow more companies to manufacture generic versions of its experimental oral antiviral Covid-19 pill. Snap has garnered 100 million Snapchat users in India. Plus, Mohit Yadav at REVOS tells Forbes India about his company's peer-to-peer EV charging network